{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+drug",
    "query": {
      "intervention": "Intravenous drug"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2905,
    "total_pages": 291,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+drug&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T23:51:32.352Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03657043",
      "title": "A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "tisotumab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 98,
      "start_date": "2019-03-20",
      "completion_date": "2022-02-08",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 21,
      "location_summary": "San Jose, California • Fort Collins, Colorado • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657043"
    },
    {
      "nct_id": "NCT04707768",
      "title": "Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia Associated With Chronic Kidney Disease (CKD)"
      ],
      "interventions": [
        {
          "name": "Vadadustat",
          "type": "DRUG"
        },
        {
          "name": "Mircera®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 456,
      "start_date": "2021-06-18",
      "completion_date": "2023-01-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 58,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04707768"
    },
    {
      "nct_id": "NCT01479348",
      "title": "Imaging Study for FdCyd and THU Cancer Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Lung Neoplasms",
        "Urinary Bladder Neoplasms",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "[F-18]-5-FLUORO-2'-DEOXYCYTIDINE",
          "type": "DRUG"
        },
        {
          "name": "Tetrahydrouridine intravenous (IV)",
          "type": "DRUG"
        },
        {
          "name": "Tetrahydrouridine (oral)",
          "type": "DRUG"
        },
        {
          "name": "Positron emission tomography (PET)/Computed tomography (CT)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 5,
      "start_date": "2011-11-01",
      "completion_date": "2019-01-11",
      "has_results": true,
      "last_update_posted_date": "2020-06-02",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479348"
    },
    {
      "nct_id": "NCT04784715",
      "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer; HER2-positive; Metastatic"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Taxane",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1157,
      "start_date": "2021-04-26",
      "completion_date": "2029-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 30,
      "location_summary": "Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784715"
    },
    {
      "nct_id": "NCT04770935",
      "title": "To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Von Willebrand's Disease (VWD)"
      ],
      "interventions": [
        {
          "name": "efanesoctocog alfa (BIVV001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-05-03",
      "completion_date": "2022-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770935"
    },
    {
      "nct_id": "NCT00927589",
      "title": "A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Cancers"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2009-07",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2015-12-10",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00927589"
    },
    {
      "nct_id": "NCT03152318",
      "title": "A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma of Brain",
        "Astrocytoma",
        "Malignant Astrocytoma",
        "Oligodendroglioma",
        "Anaplastic Oligodendroglioma of Brain (Diagnosis)",
        "Mixed Oligo-Astrocytoma",
        "Ependymoma",
        "Ganglioglioma",
        "Pylocytic/Pylomyxoid Astrocytoma",
        "Brain Tumor",
        "Glioma",
        "Brain Cancer",
        "Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "rQNestin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2017-07-18",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152318"
    },
    {
      "nct_id": "NCT06938347",
      "title": "Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Right-To-Left Shunt"
      ],
      "interventions": [
        {
          "name": "Agitated Saline SoC",
          "type": "DRUG"
        },
        {
          "name": "ASI-02",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agitated Solutions, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-11-05",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 7,
      "location_summary": "Chicago, Illinois • Rochester, Minnesota • Saint Cloud, Minnesota + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Cloud",
          "state": "Minnesota"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06938347"
    },
    {
      "nct_id": "NCT01504776",
      "title": "Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anand Jillella",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2011-04",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-09-19",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01504776"
    },
    {
      "nct_id": "NCT04524689",
      "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)"
      ],
      "interventions": [
        {
          "name": "SAR408701 (Tusamitamab ravtansine)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2020-10-26",
      "completion_date": "2024-12-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-09-15T23:51:32.352Z",
      "location_count": 1,
      "location_summary": "Westwood, Kansas",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04524689"
    }
  ]
}